Palovarotene

Drug Profile

Palovarotene

Alternative Names: Clm-001; R-667; RG-667; RO-3300074

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Clementia Pharmaceuticals; Roche
  • Class Benzoic acids; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrodysplasia ossificans progressiva
  • Preclinical Bone disorders
  • Discontinued Emphysema

Most Recent Events

  • 05 Jun 2017 Preclinical trials in Bone disorders (multiple osteochondroma) in Canada (unspecified route)
  • 05 Jun 2017 Clementia Pharmaceuticals plans a clinical trial in Multiple osteochondroma, later in 2017
  • 05 Jun 2017 Clementia Pharmaceuticals plans a phase III registration trial in Fibrodysplasia ossificans progressiva, later in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top